American Journal of Obstetrics & Gynecology
Volume 196, Issue 2 , Pages 181.e1-181.e13 , February 2007

The receptor for advanced glycation end products (RAGE) system in women with intraamniotic infection and inflammation

Received 28 April 2006 ,Revised 5 July 2006 ,Accepted 7 September 2006.

References 

  1. Green NS, Damus K, Simpson JL, Iams J, Reece EA, Hobel CJ, et al. March of Dimes Scientific Advisory Committee on Prematurity (Research agenda for preterm birth: recommendations from the March of Dimes). Am J Obstet Gynecol. 2005;193:626–635
  2. Morrison JJ, Rennie JM. Clinical, scientific and ethical aspects of fetal and neonatal care at extremely preterm periods of gestation. Br J Obstet Gynecol. 1997;104:1341–1350
  3. Lockwood CJ, Kuczynski E. Markers of risk for preterm delivery. J Perinat Med. 1999;27:5–20
  4. Grigg J, Arnon S, Chase A, Silverman M. Inflammatory cells in the lungs of premature infants on the first day of life (Perinatal risk factors and origin of cells). Arch Dis Child. 1993;69:40–43
  5. Romero R, Avila C, Brekus CA, Mazor M. The role of systemic and intrauterine infection in preterm parturition. In:  Garfield RE editors. Uterine Contractility. Norwell, MA: Serono Symposia; 1990;p. 319–354
  6. Romero R, Sirtori M, Oyarzun E, Avila C, Mazor M, Callahan R, et al. Infection and labor (V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes). Am J Obstet Gynecol. 1989;161:817–824
  7. Watts D, Krohn M, Hillier S, Eschenbach D. The association of occult amniotic fluid infection with gestational age and neonatal outcome among women in preterm labor. Obstet Gynecol. 1992;79:351-17
  8. Buhimschi IA, Christner R, Buhimschi CS. Proteomic biomarker analysis of amniotic fluid for identification of intra-amniotic inflammation. BJOG. 2005;112:173–181
  9. Buhimschi IA, Buhimschi CS, Christner R, Weiner CP. Proteomics technology for the accurate diagnosis of inflammation in twin pregnancies. BJOG. 2005;112:250–255
  10. Weiner CP, Lee K-Y, Buhimschi CS, Cristner R, Buhimschi IA. Proteomic biomarkers predictive of the success of rescue cerclage. Am J Obstet Gynecol. 2005;192:710–718
  11. Buhimschi IA, Buhimschi CS, Weiner CP, Kimura T, Hamar BD, Sfakianaki AK, et al. Proteomic but not enzyme-linked immunosorbent assay technology detects amniotic fluid monomeric calgranulins from their complexed calprotectin form. Clin Diagn Lab Immunol. 2005;12:837–844
  12. Buhimschi CS, Bhandari V, Hamar B, et al. Proteomic profiling of the amniotic fluid to detect inflammation, infection, and neonatal sepsis. PLoS Med. 2007;16:e18
  13. Heizmann CW, Fritz G, Schafer BW. S100 proteins: structure, functions and pathology. Front Biosci. 2002;7:1356–1368
  14. Vogl T, Propper C, Hartmann M, Strey A, Strupat K, van den Bos C, et al. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem. 1999;274:25291–25296
  15. Robinson MJ, Hogg N. A comparison of human S100A12 with MRP-14 (S100A9). Biochem Biophys Res Commun. 2000;275:865–870
  16. Gottsch JD, Li Q, Ashraf F, O’Brien TP, Stark WJ, Liu SH. Cytokine-induced calgranulin C expression in keratocytes. Clin Immunol. 1999;91:34–40
  17. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, et al. Neutrophil derived human S100A12 (ENRAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52:847–853
  18. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889–901
  19. Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev. 2002;54:1615–1625
  20. Chavakis T, Bierhaus A, Nawroth PP. RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect. 2004;6:1219–1225
  21. Lewis DF, Bergstedt S, Edwards MS, Burlison S, Gallaspy JW, Brooks GG, et al. Successful magnesium sulfate tocolysis: is “weaning” the drug necessary?. Am J Obstet Gynecol. 1997;177:742–745
  22. Naeye RL. Disorders of the placenta and decidua. In: Disorder of the Placenta, Fetus and Neonate: Diagnosis and Clinical Significance. St. Louis: Mosby; 1992;p. 118–247
  23. Salafia CM, Weigl C, Silberman L. The prevalence and distribution of acute placental inflammation in uncomplicated term pregnancies. Obstet Gynecol 89; 73:383–9.
  24. Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. Arthritis Rheum. 2004;50:1286–1295
  25. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998–15004
  26. Schlueter C, Hauke S, Flohr AM, Rogalla P, Bullerdiek J. Tissue-specific expression patterns of the RAGE receptor and its soluble forms--a result of regulated alternative splicing?. Biochim Biophys Acta. 2003;1630:1–6
  27. Hinkle DE, Wiersma W, Jurs SG. In Applied statistics for the behavioral sciences. 2nd ed.. Boston: Houghton Mifflin Company; 1988;
  28. Lindstrom TM, Bennett PR. The role of nuclear factor kappa B in human labour. Reproduction. 2005;130:569–581
  29. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science. 1988;242(4878):540–546
  30. Barnes PJ, Karin M. Nuclear factor-B-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066–1071
  31. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature. 1996;382(6593):685–691
  32. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert P, Chen J, et al. Diabetes-associated sustained activation of the transcription factor NF-B. Diabetes. 2001;50:2792–2809
  33. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489–497
  34. Goova MT, Li J, Kislinger T, Qu W, Lu Y, Bucciarelli LG, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol. 2001;159:513–525
  35. Gilbert WM, Brace RA. The missing link in amniotic fluid volume regulation: intramembranous absorption. Obstet Gynecol. 1989;74:748–754
  36. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther. 2005;7:R817–R824
  37. Emanuele E, D’Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol. 2005;62:1734–1736

 Supported in part by RO1 HD 047321-01 (IAB).Cite this article as: Buhimschi IA, Zhao G, Pettker CM, et al. The receptor for advanced glycation end products (RAGE) system in women with intraamniotic infection and inflammation. Am J Obstet Gynecol 2007;196:181.e1-181.e12.

PII: S0002-9378(06)01179-3

doi: 10.1016/j.ajog.2006.09.001

American Journal of Obstetrics & Gynecology
Volume 196, Issue 2 , Pages 181.e1-181.e13 , February 2007

Article Tools

* Image Usage & Resolution